Analysts expect GH Research PLC to report a consensus third-quarter loss of $0.31 per share on zero revenue, with the stock currently trading at $20.86 compared to a $45.00 average analyst price target.
Investors are primarily focused on the timing for the initiation of the company’s global Phase 3 pivotal program for GH001 in treatment-resistant depression. This follows favorable mid-2026 feedback from the FDA, which confirmed that the company’s manufacturing and aerosol delivery device plans were ready for pivotal trials. With a substantial cash position of $362.7 million reported last quarter, the market is looking for confirmation that the clinical program remains on schedule for a late 2026 launch.